| Binding affinity to mouse CCR5 - BioAssay Summary Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys. ..more |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compound: Description: Title: Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Abstract: Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys. (PMID: 18267361) Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 12406 ChEMBL target type: Target is a single protein chain Result Definitions
Data Table (Concise)
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||